Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin Receives FDA Approval for Generic Actos® Tablets

Mumbai & Baltimore, April 09, 2014: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Pioglitazone Tablets USP, 15 mg, 30 mg, and 45 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Takeda Pharmaceuticals USA, Inc.'s (Takeda) Actos® Tablets, 15 mg, 30 mg, and 45 mg. Lupin Pharmaceuticals Inc. (LPI), the company's US subsidiary would commence marketing the product shortly.

Lupin's Pioglitazone Tablets USP, 15 mg, 30 mg, and 45 mg are the AB-rated generic equivalents of Takeda's Actos® Tablets 15 mg, 30 mg, and 45 mg and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.

Actos® Tablets had annual U.S sales of US$ 236 million (IMS MAT Dec, 2013).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and the fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by revenues. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242 million) respectively. Please visit http://www.lupinworld.com for more information.

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com

For more information, please contact -

Shamsher Gorawara
Head – Corporate Communications
Ph: +91-22-66402531
Email: shamshergorawara@lupinpharma.com

or

Alpesh Dalal
Head – M & A and Investor Relations
Lupin Limited
Ph: +91 98 20 023 511
Email: alpeshdlal@lupinpharma.com

Safe Harbor Statement

* *Actos® is a registered trademark of Takeda Pharmaceutical Company Limited.*